Results 21 to 30 of about 4,104 (188)

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. [PDF]

Diabetes Metab Syndr Obes
Patients suffering from acromegaly and Cushing’s Disease (CD) face the risk of several clinical complications. The onset of diabetes mellitus (DM) is among the most important: exposure to elevated growth hormone or cortisol levels is associated with ...
De Fano M, Falorni A, Malara M, Porcellati F, Fanelli CG.   +4 more
europepmc   +2 more sources

Pasireotide as first line medical therapy for selected patients with acromegaly. [PDF]

Pituitary
Olarescu NC, Jørgensen AP, Atai S, Wiedmann MKH, Dahlberg D, Bollerslev J, Heck A.   +6 more
europepmc   +3 more sources

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide

Frontiers in Endocrinology, 2020
Acromegaly is a disease due to chronic GH excess and a consequent rise in IGF-1 levels. This rare endocrine condition is associated with metabolic alterations such as hyperglycaemia, dyslipidaemia, and systemic arterial hypertension, which, in addition ...
Soraya Puglisi, Soraya Puglisi, Francesco Ferraù, Francesco Ferraù, Marta Ragonese, Marta Ragonese, Federica Spagnolo, Federica Spagnolo, Salvatore Cannavò, Salvatore Cannavò   +9 more
doaj   +2 more sources

Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2021
ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases.
Christiaan F. Mooij, Carline E. Tacke, Mirjam E. van Albada, Winfried Barthlen, Hennie Bikker, Klaus Mohnike, Matthijs W.N. Oomen, A.S. Paul van Trotsenburg, Nitash Zwaveling-Soonawala   +8 more
doaj   +1 more source

Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease. [PDF]

JCEM Case Rep
Elhadd T, Ibrahim SI, Abdelmahmuod E, Webb SM.   +3 more
europepmc   +3 more sources

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR

Endocrine Connections, 2022
Objective: Pasireotide is a second-generation somatostatin receptor ligand (SRL) used for treating acromegaly. Its clinical use is limited by adverse effe cts on glucose homeostasis. The aim of this study was to evaluate longitudinal changes in beta-cell
Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, Philippe Chanson   +6 more
doaj   +1 more source

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience

Journal of Clinical Endocrinology and Metabolism, 2023
Context Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I).
M. Gadelha, Nelma Verônica Marques, Christhiane Fialho, Cristiane Scaf, E. Lamback, Ximene Antunes, E. Santos, Jaqueline Magalhães, L. E. Wildemberg   +8 more
semanticscholar   +1 more source

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

PLoS ONE, 2021
BackgroundAllogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant
Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, Andrew B Nixon, Jing Lyu, Daniel C Parker, James Bain, Michael Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L Huebner, Thomas Spitzer, Jami Brown, Jonathan U Peled, Marcel van den Brink, Antonio Gomes, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, Richard Lopez, David Rizzieri, Stefanie Sarantopoulos, Nelson Chao, Anthony D Sung   +28 more
doaj   +1 more source

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly

Endocrine Connections, 2020
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superio r efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide.
Mônica R Gadelha, Feng Gu, Marcello D Bronstein, Thierry C Brue, Maria Fleseriu, Ilan Shimon, Aart J van der Lely, Shoba Ravichandran, Albert Kandra, Alberto M Pedroncelli, Annamaria A L Colao   +10 more
doaj   +1 more source

Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic Peptides

Pharmaceutics, 2022
The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs.
Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss   +5 more
doaj   +1 more source